Betting on ‘Golden Age’ of Colonoscopies, Investors Buy Up Gastroenterology Practices
In 2021, the number of private equity acquisitions of gastroenterology practices grew by 28% over the previous year, according to Spherix Global Insights and Fraser Healthcare. Complex government regulations, technological innovations, and insurance industry practices have driven many gastroenterologists to sell shares in their practices, said Praveen Suthrum, who runs a consulting company for physician […]
Eylea Keeps its Lead In the Retinal Space as Physicians Remain Hesitant on Roche’s Susvimo — Report
Roche trumpeted a “major advancement” in the retinal space with the approval of its eye drug Susvimo last October, touting it as a more manageable option for patients with wet age-related macular degeneration. However, safety concerns leave some physicians hesitant. While most ophthalmologists have heard of Susvimo — 86%, according to the latest Spherix survey […]
RA Patients in Great Need of New Treatment Options
Almost half, 49 percent, of rheumatologists, decreased prescriptions of Xeljanz over the past three months, according to Spherix Global Insights’ report for the first quarter. The decline in the prescription of Rinvoq and Olumiant was not as big during the period – just under 25 percent of rheumatologists reduced their use of these JAK inhibitors…
Spherix Global Insights Announces Exhibition and Releases the Title of Their Abstract to be Presented at the 2022 ARVO Annual Meeting
Recent survey data reveals changes afoot in the neovascular (wet) age-related macular degeneration market EXTON, Pa., March 2, 2022 /PRNewswire/ — Spherix Global Insights, an independent market intelligence firm, recently collected feedback from 103 US ophthalmologists on the neovascular age-related macular degeneration (nAMD) treatment landscape. Insights from the RealTime Dynamix™ report revealed that market leader, […]
Spherix Uncovers Key Differences in the Management of Chronic Kidney Disease Patients in Europe Versus the U.S.
New analysis of European CKD non-dialysis patient chart data reveals notable differences in nephrologists’ use of renal therapies, including SGLT2 inhibitors EXTON, Pa., / April 25, 2022 / PRNewswire – The approval of several renal pipeline products in the European market has granted nephrologists new options through which they can manage their patients with chronic […]
Spherix Global Insights Finds US Primary Biliary Cholangitis Market Poised for Transformation as Pipeline Therapies Progress in Clinical Development
Four pipeline product profiles were evaluated by US gastroenterologists to assess strengths, weaknesses, and physician receptivity EXTON, Pa., March 16, 2022 /PRNewswire/ — Spherix recently surveyed 107 US gastroenterologists and conducted ten qualitative interviews (including a key opinion leader and six clinical trial participants) to assess the current and future management of primary biliary cholangitis (PBC). The […]
Roche’s Vabysmo to Offer ‘Fierce Competition’ to Regeneron’s Eylea, But a Long Market Battle Awaits: Spherix
Content Area
Report: Tecfidera, Aubagio Preferred RRMS Treatments in Canada
From: Multiple Sclerosis News Today By: Marisa Wexler MS Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights. The report was part of Spherix’s RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS treatments in Canada by […]
More Than 2,000 Patient Chart Records Reveal Shifting Tides in Kidney Patient Care
Implications abound for historic leader Amgen and newer companies with paradigm-shifting SGLT2 inhibitors (AstraZeneca [Farxiga], Vifor/Janssen [Invokana], Eli Lilly/Boehringer Ingelheim [Jardiance] and Merck [Steglatro]) EXTON, Pa., / December 7, 2021/ PRNewswire – Chronic kidney disease (CKD) patients experience a wide range of comorbidities and risks associated with their disease, such as hyperphosphatemia, secondary hyperparathyroidism (SHPT), […]
Gastroenterologists Report Challenges Treating Eosinophilic Esophagitis as New Therapies Inch Closer to FDA Approval
A high percentage of undiagnosed patients and difficulties with treatment adherence among this mostly younger male patient population could be addressed by the entrance of one or more FDA-approved therapies in the next year EXTON, Pa., November 16, 2021 /PRNewswire/ — Spherix recently surveyed 101 US gastroenterologists and followed up with ten qualitative interviews (including four with […]
